Post Profile






Amgen and Arrowhead to develop gene-therapies for heart disease

(Reuters) - Amgen Inc said on Thursday it would buy a stake in Arrowhead Pharmaceuticals Inc and team up with the company to develop gene-silencing therapies for heart disease.
read more

share

Related Posts


Alexion Pharmaceuticals, Inc. (ALXN), Amgen, Inc. (AMGN), Baxter International Inc. (BAX): The Treatment of Rare Diseases Offers Unique Opportunities

Business & Finance / Investing : Insider Monkey

A company with a modus operandi of tackling rare and very rare diseases might not necessarily jump out as a great investment, but this company has banked more than a billion dollars in annual sales doing just that. Alexion Pharmaceu...

Alvine Pharmaceuticals Reports Positive Results With ALV003 In Phase 1 Trial Of Therapy In Development For Celiac Disease

Health : Medical News Today

Alvine Pharmaceuticals, Inc., today announced proof of concept in a Phase 1 Trial of ALV003, an oral protease therapy in development to detoxify gluten, intended for use by patients with celiac disease. The trial results confirmed t...

Amgen, Inc. (AMGN), Teva Pharmaceutical Industries Ltd (ADR) (TEVA), Onyx Pharmaceuticals, Inc. (ONXX): This Biotech Envisions Green

Business & Finance / Investing : Insider Monkey

After a second offer, Amgen, Inc. (NASDAQ:AMGN) and Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX), a maker of drugs to fight cancer among other diseases, are in agreement on the offer price. The acquisition of Onyx is going to cost Amgen...

Amgen strikes deal to buy Onyx

Business & Finance : Business Report

The biotech firm Amgen has finalised a deal to buy Onyx Pharmaceuticals for $10.4-billion. ||| Washington - The world's top biotech firm, Amgen, has struck a deal to buy Onyx Pharmaceuticals for $10.4-billion, the two companies anno...

AMT Obtains License To Amgen's GDNF Gene To Develop Treatment For Parkinson's Disease With AMT's Proprietary Gene Therapy Platform

Health : Medical News Today

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced that it obtained a license from Amgen to use their GDNF gene for the development of a gene therapy treatment for Parkinson's di...

Comments


Copyright © 2016 Regator, LLC